Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GST-HG121 in Healthy Chinese Subjects
NCT05576584Phase 1Unknown
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GST-HG121 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Treatment-Related Adverse Events at Day 12. Status: unknown.
02
Drugs
GST-HG121
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05576584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576584.